Journal: American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting

Article Title: Liquid Biopsy to Identify Actionable Genomic Alterations

doi: 10.1200/EDBK_199765

Figure Lengend Snippet: Performance Characteristics of OncoBEAM RAS CRC Kit, Idylla ctKRAS, and Idylla ctNRAS-BRAF Mutation Tests

Article Snippet: ​ Despite the widespread use of liquid biopsy in solid malignancy, only five distinct test kits have government approval: Cobas EGFR Mutations Test v2 (Roche Molecular Diagnostics; FDA approval for detection of EGFR del19, EGFR L858R , and EGFR T790M in lung cancer), Therascreen EGFR RGQ Plasma PCR kit (Qiagen Inc; E.U. approval for detection of EGFR del19 and EGFR L858R in lung cancer); AmoyDx Super-ARMS EGFR mutation test (AmoyDx; Chinese Food and Drug Administration approval for detection of EGFR del19 , EGFR 858R, and EGFR T790M in lung cancer); OncoBEAM RAS CRC Kit (Sysmex Inostics; E.U. approval for detection of KRAS and NRAS mutations in colorectal cancer); and Idylla ctKRAS Mutation Test and Idylla ctNRAS-BRAF Mutation Test (Biocartis, Inc.; E.U. approval for detection of KRAS, NRAS , and BRAF mutations in colorectal cancer).

Techniques: Mutagenesis, Digital PCR, Real-time Polymerase Chain Reaction, Sequencing